<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271956</url>
  </required_header>
  <id_info>
    <org_study_id>CLL-RT1</org_study_id>
    <nct_id>NCT04271956</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation</brief_title>
  <acronym>CLL-RT1</acronym>
  <official_title>A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of Zanubrutinib (BGB-3111), a BTK Inhibitor, Plus Tislelizumab (BGB-A317), a PD1 Inhibitor, for Treatment of Patients With Richter Transformation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German CLL Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German CLL Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib&#xD;
      (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of&#xD;
      patients with Richter Transformation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Richter Transformation (RT) remains one of the biggest challenges in the treatment and&#xD;
      management of CLL. While considerable progress has been made in the treatment of CLL, the&#xD;
      prognosis of CLL patients with malignant disease transformation still is very poor and&#xD;
      reported median OS is between 6 to 8 months. Conventional approaches with chemo- and&#xD;
      chemoimmunotherapy have largely failed to improve response rates in RT patients. However, as&#xD;
      the established treatment approach for de-novo Diffuse Large B Cell Lymphoma (DLBCL) is&#xD;
      chemoimmunotherapy with a combination of Rituximab, Cyclophosphamid, Hydroxydaunorubicin,&#xD;
      Vincristin and Prednisolon (R-CHOP), this has become the most commonly used regimen for lack&#xD;
      of alternative strategies, despite poor efficacy. Patients being fit enough for allogeneic&#xD;
      transplantation are undergoing this procedure after induction with R-CHOP. However, the&#xD;
      majority of patients are not suitable for transplantation and relapse quickly. Hence, there&#xD;
      is urgent need to improve therapy of RT by testing new compounds and combinations for&#xD;
      treatment of this disease. Based on the available preclinical and preliminary clinical data&#xD;
      on checkpoint inhibition plus Bruton's tyrosine (BTK) inhibition, the current trial will&#xD;
      systematically assess the safety and toxicity of tislelizumab, a programmed cell death&#xD;
      protein 1 (PD-1) inhibitor, plus zanubrutinib, a BTK inhibitor in patients with RT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) after induction therapy according to the refined Lugano Classification (Cheson et al, 2016)</measure>
    <time_frame>18 weeks</time_frame>
    <description>Proportion of patients having achieved complete response (CR) or partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR after induction therapy according to the IWCLL criteria (Hallek et al, 2018)</measure>
    <time_frame>18 weeks</time_frame>
    <description>Proportion of patients having achieved complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR after consolidation therapy</measure>
    <time_frame>36 weeks</time_frame>
    <description>Proportion of patients having achieved complete response (CR) or partial response (PR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Time from the date of registration to the date of first occurrence of disease progression or relapse (determined according to the IWCLL guidelines and Lugano classification) or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Time from the date of registration to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Treatment (TTNT)</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Time from date of registration to the date of first subsequent CLL/RT treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 15 months</time_frame>
    <description>Time from the date of first documented response to the first occurrence of progression, relapse or death by any cause, whichever occurs first.&#xD;
Duration of response will be evaluated both according to the refined Lugano Classification as well as according to the IWCLL criteria. In the first case it will be calculated for patients with CR or PR, in the second case for patients with (clin.) CR, (clin.) CRi, PR, or PR-L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type, frequency, severity of adverse events (AEs)</measure>
    <time_frame>Up to 15 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Richter Transformation</condition>
  <arm_group>
    <arm_group_label>Tislelizumab + Zanubrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib&#xD;
Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib&#xD;
Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Cycle (q21d): Day 1: Tislelizumab i.v. 200 mg</description>
    <arm_group_label>Tislelizumab + Zanubrutinib</arm_group_label>
    <other_name>BGB-A317</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib</intervention_name>
    <description>Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day</description>
    <arm_group_label>Tislelizumab + Zanubrutinib</arm_group_label>
    <other_name>BGB-3111</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of CLL according to iwCLL criteria (Hallek et al, 2018)&#xD;
&#xD;
          2. Confirmed histopathological diagnosis of RT&#xD;
&#xD;
          3. Creatinine clearance ≥30ml/min calculated according to the modified formula of&#xD;
             Cockcroft and Gault or directly measured with 24hr urine collection&#xD;
&#xD;
          4. Adequate liver function as indicated by a total bilirubin ≤ 2x, AST/ALT ≤ 2.5 x the&#xD;
             institutional ULN value, unless directly attributable to the patient's CLL/RT or to&#xD;
             Gilbert's Syndrome, in which case a max. total bilirubin ≤ 4 x and AST/ALT ≤ 5 x the&#xD;
             institutional ULN value are required&#xD;
&#xD;
          5. Negative serological testing for hepatitis B (HBsAg negative and anti-HBc negative;&#xD;
             patients positive for anti-HBc may be included if PCR for HBV DNA is negative and&#xD;
             HBV-DNA PCR is performed every two months until 2 months after last dose of&#xD;
             zanubrutinib), negative testing for hepatitis-C RNA and negative HIV test within 6&#xD;
             weeks prior to registration&#xD;
&#xD;
          6. Age at least 18 years&#xD;
&#xD;
          7. ECOG performance status 0-2, ECOG 3 is only permitted if related to CLL or RT (e.g.&#xD;
             due to anaemia or severe constitutional symptoms)&#xD;
&#xD;
          8. Life expectancy ≥ 6 months&#xD;
&#xD;
          9. Ability and willingness to provide written informed consent and to adhere to the study&#xD;
             visit schedule and other protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who did not respond to previous line of RT therapy (i.e. primary progressive&#xD;
             patients)&#xD;
&#xD;
          2. Patients with more than one prior line of RT therapy&#xD;
&#xD;
          3. Allogenic stem cell transplantation within the last 100 days or signs of active&#xD;
             graft-versus-host disease (GVHD) after prior allogeneic stem cell transplantation&#xD;
             within any time&#xD;
&#xD;
          4. Patients with confirmed progressive multifocal leukoencephalopathy (PML)&#xD;
&#xD;
          5. Uncontrolled autoimmune condition&#xD;
&#xD;
          6. Malignancies other than CLL currently requiring systemic therapies&#xD;
&#xD;
          7. Active infection currently requiring systemic treatment&#xD;
&#xD;
          8. Any comorbidity or organ system impairment rated with a Cumulative Illness Rating&#xD;
             Scale (CIRS) score of 4, excluding the eyes/ears/nose/throat/larynx organ system, or&#xD;
             any other life-threatening illness, medical condition or organ system dysfunction that&#xD;
             - in the investigator´s opinion could comprise the patients safety or interfere with&#xD;
             the absorption or metabolism of the study drugs&#xD;
&#xD;
          9. Requirement of therapy with strong CYP3A4 inhibitors/inducers&#xD;
&#xD;
         10. Requirement of therapy with phenprocoumon or other vitamin K antagonists.&#xD;
&#xD;
         11. Use of investigational agents, e.g. monoclonal antibodies or other experimental drugs&#xD;
             within clinical trials, which might interfere with the study drug within 28 days (or 5&#xD;
             times half-life [t1/2] of the compound, whichever is longer) prior to registration&#xD;
&#xD;
         12. Known hypersensitivity to tislelizumab, zanubrutinib or any of the excipients&#xD;
&#xD;
         13. Pregnant women and nursing mothers (a negative pregnancy test is required for all&#xD;
             women of childbearing potential within 7 days before start of treatment)&#xD;
&#xD;
         14. Fertile men or women of childbearing potential unless:&#xD;
&#xD;
               -  surgically sterile or ≥ 2 years after the onset of menopause, or&#xD;
&#xD;
               -  willing to use two methods of reliable contraception including one highly&#xD;
                  effective contraceptive method (Pearl Index &lt;1) and one additional effective&#xD;
                  (barrier) method during study treatment and for 12 months after the end of study&#xD;
                  treatment.&#xD;
&#xD;
         15. Vaccination with a live vaccine &lt;28 days prior to randomization&#xD;
&#xD;
         16. Legal incapacity&#xD;
&#xD;
         17. Prisoners or subjects who are institutionalized by regulatory or court order&#xD;
&#xD;
         18. Persons who are in dependence to the sponsor or an investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara Eichhorst, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department I of Internal Medicine, University Hospital Cologne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Eichhorst, Prof.</last_name>
    <phone>+4922147888220</phone>
    <email>barbara.eichhorst@uk-koeln.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Othman Al-Sawaf, MD</last_name>
    <phone>+4922147888220</phone>
    <email>othman.al-sawaf@uk-koeln.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H.O.T Praxis Landshut</name>
      <address>
        <city>Landshut</city>
        <zip>84036</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>München Klinik Schwabing</name>
      <address>
        <city>Munich</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brüderkrankenhaus St. Josef Paderborn</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.dcllsg.de/en/trial/cll-rt1/index.php</url>
    <description>Click here for more information about this study: CLL-RT1 (German CLL Study Group)</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

